FDA Approves Blujepa: A New Class of Oral Antibiotic for Urinary Tract Infections

FDA greenlights Blujepa, the first new oral antibiotic for uUTIs in 30 years, targeting resistance with a novel dual enzyme mechanism.

#fda, #antibiotics, #urinary tract infections, #gsk, #healthcare

FDA's Dr. Peter Marks Resigns Amid Controversy Over Vaccine Misinformation

Dr. Peter Marks resigns as Director of the CBER at the FDA, citing Health and Human Services Secretary RFK Jr.'s vaccine misinformation. His departure highlights the clash between political appointments and scientific integrity.

#fda, #peter marks, #vaccine misinformation, #rfk jr, #health